BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jenner P, Mori A, Kanda T. Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease? Parkinsonism & Related Disorders 2020;80:S28-36. [DOI: 10.1016/j.parkreldis.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sikka P, Behl T, Chandel P, Sehgal A, Singh S, Makeen HA, Albratty M, Alhazmi HA, Meraya AM. Scrutinizing the Therapeutic Promise of Purinergic Receptors Targeting Depression. Neurotox Res 2022. [PMID: 35930172 DOI: 10.1007/s12640-022-00550-2] [Reference Citation Analysis]
2 Mori A, Chen JF, Uchida S, Durlach C, King SM, Jenner P. The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease. Molecules 2022;27:2366. [PMID: 35408767 DOI: 10.3390/molecules27072366] [Reference Citation Analysis]
3 Angela Cenci M, Skovgård K, Odin P. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jost WH, Tönges L. [Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?]. Fortschr Neurol Psychiatr 2022. [PMID: 35226930 DOI: 10.1055/a-1771-6225] [Reference Citation Analysis]
5 Schneider JS, Kortagere S. Current concepts in treating mild cognitive impairment in Parkinson's disease. Neuropharmacology 2022;203:108880. [PMID: 34774549 DOI: 10.1016/j.neuropharm.2021.108880] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pasquini S, Contri C, Merighi S, Gessi S, Borea PA, Varani K, Vincenzi F. Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets. Int J Mol Sci 2022;23:1219. [PMID: 35163142 DOI: 10.3390/ijms23031219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Shimo Y, Maeda T, Chiu SW, Yamaguchi T, Kashihara K, Tsuboi Y, Nomoto M, Hattori N, Watanabe H, Saiki H; J-FIRST Group. Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST). Parkinsonism Relat Disord 2021;91:115-20. [PMID: 34583302 DOI: 10.1016/j.parkreldis.2021.09.015] [Reference Citation Analysis]
8 Jenner P, Mori A, Aradi SD, Hauser RA. Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's disease. Expert Rev Neurother 2021;21:317-33. [PMID: 33507105 DOI: 10.1080/14737175.2021.1880896] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]